Tom 19, Nr 4 (2023)
Artykuł przeglądowy sponsorowany
Opublikowany online: 2023-12-12
Wyświetlenia strony 296
Wyświetlenia/pobrania artykułu 129
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Rola apomorfiny w terapii choroby Parkinsona

Tomasz Chmiela1, Joanna Siuda1
Pol. Przegl. Neurol 2023;19(4):302-312.

Streszczenie

W terapii choroby Parkinsona (PD, Parkinsons’s disease) apomorfinę wykorzystuje się w postaci powtarzalnych podskórnych wstrzyknięć oraz ciągłego wlewu podskórnego. Podskórne wstrzyknięcia są stosowane w leczeniu nagłych stanów off, a ciągły wlew apomorfiny — w terapii zaawansowanej PD. Jest skuteczną metodą pozwalającą zmniejszyć zarówno liczbę stanów off, jak i fluktuacji ruchowych. Ciągły wlew apomorfiny, ze względu na niższą inwazyjność w porównaniu z pozostałymi metodami leczenia zaawansowanej PD, może być szczególnie korzystny u pacjentów na wcześniejszych etapach choroby. Ponadto jest postępowaniem w pełnic odwracalnym i może poprzedzać inne metody terapii zaawansowanej PD, takie jak głęboka stymulacja mózgu czy dojelitowe podawanie żelu z lewodopą i karbidopą.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc. 1951; 56: 251–253.
  2. Agid Y, Pollak P, Bonnet AM, et al. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet. 1979; 1(8116): 570–572.
  3. Corsini GU, Del Zompo M, Gessa GL, et al. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet. 1979; 1(8123): 954–956.
  4. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984; 107(Pt 2): 487–506.
  5. Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet. 1987; 1(8537): 871.
  6. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain. 2009; 132(Pt 11): 2947–2957.
  7. Sauerbier A, Jenner P, Todorova A, et al. Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord. 2016; 22 Suppl 1: S41–S46.
  8. Sławek J. Zaawansowana choroba Parkinsona — jak poprawić jej rozpoznawalność i właściwie kwalifikować chorych do terapii zaawansowanych? Pol Przegl Neurol. 2020; 16(3): 161–171.
  9. Krüger R, Klucken J, Weiss D, et al. Classification of advanced stages of Parkinson's disease: translation into stratified treatments. J Neural Transm (Vienna). 2017; 124(8): 1015–1027.
  10. Titova N, Martinez-Martin P, Katunina E, et al. Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed. J Neural Transm (Vienna). 2017; 124(12): 1529–1537.
  11. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004; 62(6 Suppl 4): S8–11.
  12. Gancher S. Pharmacokinetics of apomorphine in Parkinson's disease. J Neural Transm. 1995; 45(Suppl): 137–141.
  13. Fahn S, Oakes D, Shoulson I, et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351(24): 2498–2508.
  14. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. Mov Disord. 1995; 10(1): 37–43.
  15. Kempster PA, Frankel JP, Stern GM, et al. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990; 53(11): 1004–1007.
  16. Merello M, Pikielny R, Cammarota A, et al. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in parkinsonʼs disease patients. Clin Neuropharmacol. 1997; 20(2): 165–167.
  17. Hellmann MA, Sabach T, Melamed E, et al. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease. Biomed Pharmacother. 2008; 62(4): 250–252.
  18. Papuć E, Trzciniecka O, Rejdak K. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease. Ann Agric Environ Med. 2019; 26(1): 133–137.
  19. Politis M, Wu K, Molloy S, et al. Parkinson's disease symptoms: the patient's perspective. Mov Disord. 2010; 25(11): 1646–1651.
  20. Pahwa R, Koller WC, Trosch RM, et al. APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007; 258(1-2): 137–143.
  21. Gunzler SA, Koudelka C, Carlson NE, et al. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol. 2008; 65(2): 193–198.
  22. Trenkwalder C, Chaudhuri KR, García Ruiz PJ, et al. Expert Consensus Group for Use of Apomorphine in Parkinson's Disease. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease — clinical practice recommendations. Parkinsonism Relat Disord. 2015; 21(9): 1023–1030.
  23. Hagell P, Odin P. Apomorphine in Parkinson’s disease. 3rd ed. UNI-MED, Bremen 2014.
  24. Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011; 1(2): 197–203.
  25. Clinical review report: apomorphine (Movapo). (Paladin Labs Inc.): Indication: The acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson’s disease [Internet]. Canadian Agency for Drugs and Technologies in Health, Ottawa 2018: Ottawa.
  26. García Ruiz PJ, Sesar Ignacio Á, Ares Pensado B, et al. Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. Mov Disord. 2008; 23(8): 1130–1136.
  27. Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism Relat Disord. 2017; 45: 33–38.
  28. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018; 17(9): 749–759.
  29. Katzenschlager R, Poewe W, Rascol O, et al. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021; 83: 79–85.
  30. García Ruiz PJ, Ignacio ÁS, Pensado BA, et al. Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. Mov Disord. 2008; 23(8): 1130–1136.
  31. Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism Relat Disord. 2017; 45: 33–38.
  32. van Laar T, Postma AG, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism Relat Disord. 2010; 16(1): 71–72.
  33. Mathers SE, Kempster PA, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry. 1988; 51(12): 1503–1507.
  34. Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol. 1993; 33(5): 490–493.
  35. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord. 1996; 11(6): 729–732.
  36. Factor SA, Brown D, Molho E. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord. 2001; 15(1): 167–169, doi: 10.1002/1531-8257(200001)15:1<167::aid-mds1029>3.0.co;2-8.
  37. Coelho M, Ferreira J, Rosa M, et al. Treatment options for non-motor symptoms in late-stage Parkinson's disease. Expert Opin Pharmacother. 2008; 9(4): 523–535.
  38. Tribl GG, Sycha T, Kotzailias N, et al. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry. 2005; 76(2): 181–185.
  39. Haba-Rubio J, Staner L, Cornette F, et al. Acute low single dose of apomorphine reduces periodic limb movements but has no significant effect on sleep arousals: a preliminary report. Neurophysiol Clin. 2003; 33(4): 180–184.
  40. Magennis B, Cashell A, O’Brien D, et al. An audit of apomorphine in the management of complex idiopathic Parkinson’s disease in Ireland. Mov Disord. 2012; 27(Suppl. 1): S44.
  41. Fox SH, Katzenschlager R, Lim SY, et al. Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018; 33(8): 1248–1266.
  42. Dafsari HS, Martinez-Martin P, Rizos A, et al. EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Mov Disord. 2019; 34(3): 353–365.
  43. Ondo WG, Hunter C, Ferrara JM, et al. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012; 18(5): 619–622.
  44. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998; 65(5): 709–716.
  45. Sigurdardóttir GR, Nilsson C, Odin P, et al. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta Neurol Scand. 2001; 104(2): 92–96.
  46. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998; 64(5): 573–576.
  47. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks — facts and fiction: a critical review. Adv Neurol. 2003; 91: 335–341.
  48. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ. 2002; 324(7352): 1483–1487.
  49. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998; 64(5): 573–576.
  50. García Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease. Mov Disord. 2006; 21(5): 727–728.
  51. Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand. 1999; 100(3): 163–167.
  52. Chou KL, Stacy M, Simuni T, et al. The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? Parkinsonism Relat Disord. 2018; 51: 9–16.
  53. Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018; 34(12): 2063–2073.
  54. Hagell P, Odin P. Apomorphine in Parkinson’s disease. 3rd ed. UNI-MED, Bremen 2014: Bremen.
  55. Dijk JM, Espay AJ, Katzenschlager R, et al. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When? J Parkinsons Dis. 2020; 10(s1): S65–S73.
  56. Krüger R, Hilker R, Winkler C, et al. Advanced stages of PD: interventional therapies and related patient-centered care. J Neural Transm (Vienna). 2016; 123(1): 31–43.
  57. Gancher S. Pharmacokinetics of apomorphine in Parkinson's disease. J. Neural Transm. 1995; 45(Suppl): 137–141.
  58. Hagell P, Odin P. Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs. 2001; 33(1): 21–34, 37.
  59. Hughes AJ. Apomorphine test in the assessment of parkinsonian patients: a meta-analysis. Adv Neurol. 1999; 80: 363–368.
  60. Odin P, Ray Chaudhuri K, Slevin JT, et al. National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015; 21(10): 1133–1144.
  61. Drapier S, Gillioz AS, Leray E, et al. Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord. 2012; 18(1): 40–44.
  62. Fernández-Pajarín G, Sesar Á, Jiménez Martín I, et al. Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: A prospective study of 22 patients. Clin Park Relat Disord. 2022; 6: 100129.
  63. Nyholm D, Constantinescu R, Holmberg B, et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand. 2009; 119(5): 345–348.
  64. Bogucki A, Budrewicz S, Gajos A, et al. Leczenie zaawansowanej choroby Parkinsona — rekomendacje Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych (2023). Pol Przegl Neurol. 2023; 19(4): 259–267.
  65. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord. 2014; 29(4): 454–462.
  66. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15): 2129–2170.